Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside.

In the more than 50 years since the founding of the National Heart, Lung, and Blood Institute and the American Heart Association, medical science has moved from an era in which hypercholesterolemia, as it is now defined, was not believed to be abnormal to one in which controlling hypercholesterolemia is known to reduce not only coronary artery disease morbidity and mortality but also total mortality. While the efforts and successes of many researchers involved in this evolution are impressive, atherosclerosis is still a major cause of death and disability in many developed nations, mostly in the form of myocardial infarction and stroke, and is an increasing cause of morbidity and mortality in developing nations. Many questions about the detailed pathogenesis of the disease remain. Elucidating the roles of high-density lipoprotein, other lipoproteins, and homocysteine, as well as the roles of cytokines and growth factors, will permit better understanding and treatment of atherosclerosis. With continuing support for research and encouragement of physicians and patients to follow recommended preventive regimens, further progress can be made against this major cause of death.

[1]  D. V. Slyke,et al.  Quantitative clinical chemistry , 1931 .

[2]  C. Muller ANGINA PECTORIS IN HEREDITARY XANTHOMATOSIS , 1939 .

[3]  C. Anfinsen On the Role of Lipemia Clearing Factor in Lipid Transport , 1954 .

[4]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[5]  P. Wood,et al.  Dietary regulation of cholesterol metabolism. , 1966, Lancet.

[6]  R. Lees,et al.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. , 1967, The New England journal of medicine.

[7]  E. Buskirk The National Diet-Heart Study Final Report. , 1969, Circulation.

[8]  J. Oncley,et al.  Lipoproteins--a current perspective of methods and concepts. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Larosa,et al.  A specific apoprotein activator for lipoprotein lipase. , 1970, Biochemical and biophysical research communications.

[10]  Ancel Keys Coronary heart disease in seven countries. , 1971, The Medical journal of Australia.

[11]  A. Gotto,et al.  Studies on the protein defect in Tangier disease. Isolation and characterization of an abnormal high density lipoprotein. , 1972, The Journal of clinical investigation.

[12]  R. Levy,et al.  The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. , 1972, The Journal of clinical investigation.

[13]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.

[14]  R. Ross,et al.  A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Gotto,et al.  A molecular theory of lipid—protein interactions in the plasma lipoproteins , 1974, FEBS letters.

[16]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.

[17]  D. Grafnetter,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.

[18]  M. Brown,et al.  The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. , 1980, Journal of supramolecular structure.

[19]  Jeremy N. Morris,et al.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. , 1980 .

[20]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Steinberg Lipoproteins and atherosclerosis. A look back and a look ahead. , 1983, Arteriosclerosis.

[22]  W. Castelli,et al.  Epidemiology of coronary heart disease: the Framingham study. , 1984, The American journal of medicine.

[23]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[24]  S. Kelsey,et al.  The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[25]  L. Wilkins Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. , 1985, Nutrition reviews.

[26]  R. Mahley,et al.  Lipoproteins of Special Significance in Atherosclerosis , 1985 .

[27]  J. Hupp Lowering Blood Cholesterol to Prevent Heart Disease , 1985, International Journal of Technology Assessment in Health Care.

[28]  D. Steinberg,et al.  A Novel Mechanism by which High Density Lipoprotein Selectively Delivers Cholesterol Esters to the Liver , 1986 .

[29]  R. Ross The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[30]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[31]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[32]  W. A. Bradley,et al.  Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100 , 1986, Nature.

[33]  T. Parker,et al.  Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. , 1987, The Journal of clinical investigation.

[34]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[35]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[36]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[37]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[38]  S. Azen,et al.  Effects of colestipol-niacin therapy on human femoral atherosclerosis. , 1991, Circulation.

[39]  H. Esterbauer,et al.  Role of vitamin E in preventing the oxidation of low-density lipoprotein. , 1991, The American journal of clinical nutrition.

[40]  B. Lewis,et al.  Effects on Coronary Artery Disease of Lipid-Lowering Diet, or Diet Plus Cholestyramine, in the St. Thomasʼ Artherosclerosis Regression Study (STARS) , 1992 .

[41]  S. Hulley,et al.  Health policy on blood cholesterol. Time to change directions. , 1992, Circulation.

[42]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[43]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[44]  Vesa Manninen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.

[45]  J. Fruchart,et al.  Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. , 1992, Clinical chemistry.

[46]  M. Sanmarco,et al.  Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.

[47]  Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.

[48]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[49]  P. Libby Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[50]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[51]  J. Breslow,et al.  Apolipoprotein E and the apolipoprotein E-deficient mouse. , 1995, Annual review of nutrition.

[52]  G. Assmann,et al.  A unique genetic and biochemical presentation of fish-eye disease. , 1995, The Journal of clinical investigation.

[53]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[54]  D. Kromhout Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[55]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[56]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[57]  A. Tall,et al.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.

[58]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[59]  M. Brown,et al.  A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .

[60]  J. Strong,et al.  The PDAY Study: Natural History, Risk Factors, and Pathobiology , 1997, Annals of the New York Academy of Sciences.

[61]  The role of antioxidants in preventive cardiology. , 1997, Current opinion in cardiology.

[62]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[63]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Steinberg Oxidative Modification of LDL and Atherogenesis , 1998 .

[65]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[66]  P. McBride,et al.  Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. , 1998, Archives of internal medicine.

[67]  The cholesterol myth. , 2000 .